Review on willingness to participate in HIV trials

J. Pharm. Pharmacogn. Res., vol. 10, no. 4, pp. 768-781, July-August 2022.

Review

Willingness to volunteer in future HIV vaccine clinical trials: A literature review and evidence synthesis

[Disposición para ser voluntario en futuros ensayos clínicos de vacunas contra el VIH: Revisión de la literatura y síntesis de evidencia]

Tram N.T. Huyen1, Somying Pumtong1, Sermsiri Sangroongruangsri 1, Luerat Anuratpanich1,2*

1Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
2Department of Pharmacy, Division of Social and Administrative Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand.
*E-mail: luerat.anu@mahidol.ac.th

Abstract

Context: Developing an effective vaccine for HIV/AIDS is a global endeavor requiring the participation of willing volunteers.

Aims: To evaluate the willingness of the global population to undergo vaccination and participate in clinical trials.

Methods: Following PRISMA guidelines, relevant studies published from January 2005 to December 2019 that reported quantitative, qualitative, and mixed analyses in peer-reviewed research papers were sought in the major databases. The inclusion criteria were that the studies be related to the willingness of participants to undergo HIV vaccination and submit to subsequent clinical trials, that they are in English, conducted in any geographic location, and published during the target period. The exclusion criteria were grey literature and studies involving the stakeholders, medical students or medical fraternities, seropositive parents with seronegative offspring, the vaccine’s biochemical, immunological, or financial aspects, and participants below the age of 16. Systematic reviews, letters to the editor, and case studies were also excluded.

Results: The selected databases initially yielded 334 articles, of which 27 remained after applying the inclusion and exclusion criteria. Demographic data, motivating factors, and the volunteers’ willingness levels were collected and analyzed.

Conclusions: This review offers guidance for future research, including a standardized scale to predict the willingness of potential volunteer groups.

Keywords: clinical trials; HIV; review; vaccination; volunteers; willingness.

jppres_pdf_free

Resumen

Contexto: Desarrollar una vacuna efectiva para el VIH/SIDA es un esfuerzo global que requiere la participación de voluntarios dispuestos.

Objetivos: Evaluar la disposición de la población mundial a vacunarse y participar en ensayos clínicos.

Métodos: Siguiendo las pautas PRISMA, se buscaron en las principales bases de datos estudios relevantes publicados entre enero de 2005 y diciembre de 2019 que informaron análisis cuantitativos, cualitativos y mixtos en artículos de investigación revisados ​​por pares. Los criterios de inclusión fueron que los estudios estuvieran relacionados con la disposición de los participantes a vacunarse contra el VIH y someterse a ensayos clínicos posteriores, que estuvieran en inglés, realizados en cualquier ubicación geográfica y publicados durante el período objetivo. Los criterios de exclusión fueron literatura gris y estudios que involucraran a las partes interesadas, estudiantes de medicina o fraternidades médicas, padres seropositivos con hijos seronegativos, aspectos bioquímicos, inmunológicos o financieros de la vacuna, y participantes menores de 16 años. Revisiones sistemáticas, cartas al editor, y los estudios de casos también fueron excluidos.

Resultados: Las bases de datos seleccionadas arrojaron inicialmente 334 artículos, de los cuales quedaron 27 después de aplicar los criterios de inclusión y exclusión. Se recopilaron y analizaron datos demográficos, factores motivadores y niveles de disposición de los voluntarios.

Conclusiones: Esta revisión ofrece orientación para futuras investigaciones, incluida una escala estandarizada para predecir la disposición de los posibles grupos de voluntarios.

Palabras Clave: disposición; ensayos clínicos; VIH; revisión; vacunación; voluntarios.

jppres_pdf_free

Citation Format: Huyen TNT, Pumtong S, Sanroongruangsri S, Anuratpanich L (2022) Willingness to volunteer in future HIV vaccine clinical trials: A literature review and evidence synthesis. J Pharm Pharmacogn Res 10(4): 768–781.
References

Asiki G, Abaasa A, Ruzagira E, Kibengo F, Bahemuka U, Mulondo J, Seeley J, Bekker LG, Delany S, Kaleebu P (2013) Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda. Vaccine 31: 5055–5061.

Bakari M, Munseri P, Francis J, Aris E, Moshiro C, Siyame D, Janabi M, Ngatoluwa M, Aboud S, Lyamuya E (2013) Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania-the phase I/II HIVIS 03 trial. BMC Public Health 13: 1149.

Becker MH (1974) The health belief model and personal health behavior. Health Educ Monogr 2: 324–473.

Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E (2004) Determinants of enrollment in a preventive HIV vaccine trial: Hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr 36: 604–612.

Chakrapani V, Newman PA, Shunmugam M, Mcluckie A, Melwin F (2007) Structural violence against Kothi-identified men who have sex with men in Chennai, India: a qualitative investigation. AIDS Educ Prev 19: 346–364.

Chakrapani V, Newman PA, Singhal N, Jerajani J, Shunmugam M (2012) Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: A social ecological approach. PLOS ONE 7: e51080.

Das K, Arnold E (2013) HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Curr Opin Virol 3: 111–118.

Detoc M, Gagneux-Brunon A, Lucht F, Botelho-Nevers E (2017) Barriers and motivations to volunteers’ participation in preventive vaccine trials: A systematic review. Expert Rev Vaccines 16: 467–477.

Dhalla S, Poole G (2011a) Barriers of enrolment in HIV vaccine trials: A review of HIV vaccine preparedness studies. Vaccine 29: 5850–5859.

Dhalla S, Poole G (2011b) Motivators of enrolment in HIV vaccine trials: A review of HIV vaccine preparedness studies. AIDS Care 23: 1430–1447.

Dhalla S, Poole G (2014) Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention. Hum Vaccin Immunother 10: 1974–84.

Dong Y, Shen X, Guo R, Liu B, Zhu L, Wang J, Zhang L, Sun J, Zhang X, Xu J (2014) Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in China. PLOS ONE 9: e111321.

Doshi M, Avery L, Kaddu RP, Gichuhi M, Gakii G, Du Plessis E, Dutta S, Khan S, Kimani J, Lorway RR (2017) Contextualizing willingness to participate: Recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials. BMC Public Health 17: 469.

Esparza J, Bhamarapravati N (2000) Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how? Lancet 355: 2061–2066.

Etcheverry MF, Evans JL, Sanchez E, Mendez-Arancibia E, Meroño M, Gatell JM, Page K, Joseph J (2013) Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials. Hum Vaccin Immunother 9: 420–429.

Etcheverry MF, Lum PJ, Evans JL, Sanchez E, De Lazzari E, Mendez-Arancibia E, Sierra E, Gatell JM, Page K, Joseph J (2011) HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco. Vaccine 29: 1991–1996.

Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Orelind K, Gee C, Hirsch A, Ippolito T, Luck A, Longhi M (2003) Candidate HIV/AIDS vaccines: Lessons learned from the World’s first phase III efficacy trials. AIDS 17: 147–156.

Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, Cáceres C, Cunningham WE (2011) Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: Barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS 22: 256–262.

Garcia F, Plana M, Climent N, Leon A, Gatell JM. Gallart T (2013) Dendritic cell based vaccines for HIV infection: The way ahead. Hum Vaccin Immunother 9: 2445–2452.

Gellin B, Modlin JF, Hu DJ, Vitek CR, Bartholow B, Mastro TD (2003) Key issues for a potential human immunodeficiency virus vaccine. Clin Infect Dis 36: 638–644.

Joseph J, Etcheverry F, Alcamí J, Maria G (2005) A safe, effective and affordable HIV vaccine—an urgent global need. AIDS Rev 7: 131–138.

Kafaar Z, Kagee A, Lesch A, Swartz L (2007) Is participation in HIV vaccine trials a health promoting behaviour? AIDS Care 19: 1307–1309.

Kakinami L, Newman PA, Lee SJ, Duan N (2008) Differences in HIV vaccine acceptability between genders. AIDS Care 20: 542–546.

Koff WC, Russell ND, Walport M, Feinberg MB, Shiver JW, Karim SA, Walker BD, Mcglynn MG, Nweneka CV, Nabel GJ (2013) Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the decade of vaccines. Vaccine 31: B204–B208.

Kpanake L, Gbandey S, Sorum PC, Mullet E (2016) Acceptability of vaccination against HIV: A mapping of Togolese people’s positions. J Health Psychol 23: 800–806.

Lally M, Gaitanis M, Vallabhaneni S, Reinert S, Mayer K, Zimet G, Rich J (2006) Willingness to receive an HIV vaccine among incarcerated persons. Prev Med 43: 402–405.

Li Q, Luo F, Zhou Z, Li S, Liu Y, Li D, Shi W, Raymond H, Ruan Y, Shao Y (2010) Willingness to participate in HIV vaccine clinical trials among Chinese men who have sex with men. Vaccine 28: 4638–4643.

Lieberman-Blum SS, Fung HB, Bandres JC (2008) Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 30: 1228–1250.

Mahy M, Marsh K, Sabin K, Wanyeki I, Daher J, Ghys PD (2019) HIV estimates through 2018: Data for decision-making. AIDS 33: S203.

Mbunda T, Tarimo EA, Bakari M, Sandström E, Kulane A (2019) Recruitment using respondent driven sampling, risk behaviors assessment and willingness of young female sex workers (18–25 years) in Dar Es Salaam, Tanzania to participate in HIV vaccine trials. BMC Public Health 19: 1537.

Métifiot M, Marchand C, Pommier Y (2013) HIV integrase inhibitors: 20-year landmark and challenges. Adv Pharmacol 67: 75–105.

Middelkoop K, Myer L, Mark D, Mthimunye SP, Smit J, Wood R, Bekker LG (2008) Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa. J Adolesc Health 43: 8–14.

Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, Sulway C, Wilson K (2004) Barriers to participating in an HIV vaccine trial: A systematic review. AIDS 18: 2235–2242.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4: 1.

Myers DG, Smith SM (2012) Exploring social psychology. New York: McGraw-Hill.

Newman PA, Chakrapani V, Weaver J, Shunmugam M, Rubincam C (2014) Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India. Vaccine 32: 5854–5861.

Newman PA, Duan N, Lee SJ, Rudy E, Seiden D, Kakinami L, Cunningham W (2007) Willingness to participate in HIV vaccine trials: The impact of trial attributes. Prev Med 44: 554–557.

Newman PA, Logie C (2010) HIV vaccine acceptability: A systematic review and meta-analysis. AIDS 24: 1749–1756.

Nyaoke BA, Mutua GN, Sajabi R, Nyasani D, Mureithi MW, Anzala OA (2017) Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya. PLOS ONE 12: e0183788.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews BMJ 372: n71.

Perisse AR, Schechter M, Moreira RI, Do Lago RF, Santoro-Lopes G, Harrison LH (2000) Willingness to participate in HIV vaccine trials among men who have sex with men in Rio de Janeiro, Brazil. Projeto Praca Onze Study Group. J Acquir Immune Defic Syndr 25: 459–463.

Poole G (2012) Using psychological principles to narrow the intention-behavior gap and increase participation in HIV vaccine trials. Curr HIV Res 10: 552–556.

Priddy FH, Cheng AC, Salazar LF, Frew PM (2006) Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US. Int J STD AIDS 17: 99–102.

Puls RL, Emery S (2006) Therapeutic vaccination against HIV: current progress and future possibilities. Clin Sci 110: 59–71.

Ravert RD, Zimet GD (2009) College student invulnerability beliefs and HIV vaccine acceptability. Am J Health Behav 33: 391–399.

Rosenstock IM (1966) Why people use health services. The Milbank Memorial Fund Quarterly 44: 94–124.

Rosenstock IM (1974) Historical origins of the health belief model. Health Educ Monogr 2: 328–335.

Rosenstock IM, Strecher VJ, Becker MH (1988) Social learning theory and the health belief model. Health Educ Q 15: 175–183.

Sahay S, Mehendale S, Sane S, Brahme R, Brown A, Charron K, Beyrer C, Bollinger R, Paranjape R (2005) Correlates of HIV vaccine trial participation: an Indian perspective. Vaccine 23: 1351–1358.

Smit J, Middelkoop K, Myer L, Seedat S, Bekker L, Stein D (2006) Willingness to participate in HIV vaccine research in a peri-urban South African community. Int J STD AIDS 17: 176–179.

Starace F, Wagner T, Luzi A, Cafaro L, Gallo P, Rezza G (2006) Knowledge and attitudes regarding preventative HIV vaccine clinical trials in Italy: Results of a national survey. AIDS Care 18: 66–72.

Suhadev M, Nyamathi AM, Swaminathan S, Suresh A, Venkatesan P (2009) Factors associated with willingness to participate in HIV vaccine trials among high-risk populations in South India. AIDS Res Hum Retroviruses 25: 217–224.

Suhadev M, Nyamathi AM, Swaminathan S, Venkatesan P, Raja Sakthivel M, Shenbagavalli R, Suresh A, Fahey JL (2006) A pilot study on willingness to participate in future preventive HIV vaccine trials. Indian J Med Res 124: 631–640.

Tarimo EA, Ambikile J, Munseri P, Bakari M (2019) Perception of potential harm and benefits of HIV vaccine trial participation: A qualitative study from urban Tanzania. PLOS ONE 14: e0224831.

Tarimo EA, Thorson A, Kohi TW, Bakari M, Mhalu F, Kulane A (2011) Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania. PLOS ONE 6: e14619.

Thabethe S, Slack C, Lindegger G, Wilkinson A, Wassenaar D, Kerr P, Bekker LG, Mngadi K, Newman PA (2018) “Why don’t you go into suburbs? Why are you targeting us?”: Trust and mistrust in HIV vaccine trials in South Africa. J Empir Res Hum Res Ethics 13: 525–536.

Wensing AM, Van Maarseveen NM, Nijhuis M (2010) Fifteen years of HIV protease inhibitors: Raising the barrier to resistance. Antivir Res 85: 59–74.

Yin L, Zhang Y, Qian HZ, Rui B, Zhang L, Zhu J, Guan Y, Wang Y, Li Q, Ruan Y (2008) Willingness of Chinese injection drug users to participate in HIV vaccine trials. Vaccine 26: 762–768.

Young AM, Diclemente RJ, Halgin DS, Sterk CE, Havens JR (2014) HIV vaccine acceptability among high-risk drug users in Appalachia: A cross-sectional study. BMC Public Health 14: 537.

Zhou F, Gao L, Li S, Li D, Zhang L, Fan W, Yang X, Yu M, Xiao D, Yan L (2012) Willingness to accept HIV pre-exposure prophylaxis among Chinese men who have sex with men. PLOS ONE 7: e32329.

© 2022 Journal of Pharmacy & Pharmacognosy Research (JPPRes)